Amgen, AstraZeneca's tezepelumab hits goal in asthma phase 3

A phase 3 trial of Amgen and AstraZeneca’s tezepelumab in severe asthma patients has met its primary endpoint. The thymic stromal lymphopoietin inhibitor drove reductions in exacerbations in patients with low levels of eosinophils, teeing the partners up to target a large, underserved portion of the asthma market.